January 26, 2015 4:46 PM ET

Healthcare Providers and Services

Company Overview of Eddingpharm (Cayman) Inc.

Company Overview

Eddingpharm (Cayman) Inc. operates as a pharmaceuticals marketing company. The company engages in in-licensing, marketing, and distributing hospital pharmaceutical products in Hong Kong and China. It offers nutritional supplements, oncology drugs, and other pharmaceuticals. The company also offers products including Telatinib, an anti-angiogenic for gastric and solid tumors, ACTB1003, a multi-mode oral kinase inhibitor, and ACTB1010, a mitotic Aurora kinase oral inhibitor. The company has a joint venture with Chiesi Farmaceutici S.p. A to establish Chiesi Edding Hong Kong Limited. Eddingpharm (Cayman) Inc. is based in Wanchai, Hong Kong.

Suite 4804

48/F Central Plaza

18 Harbour Road


Hong Kong


852 2877 4866


852 2877 4966

Key Executives for Eddingpharm (Cayman) Inc.

Senior Vice President of Finance
Chief Operating Officer
Senior Vice President of Distribution
Director of Legal Department
Compensation as of Fiscal Year 2014.

Eddingpharm (Cayman) Inc. Key Developments

Eddingpharm (Cayman) Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 01:00 PM

Eddingpharm (Cayman) Inc. Presents at 2013 BIO Convention in China, Nov-13-2013 01:00 PM. Venue: China National Convention Center, No.7 Tianchen East Road, Chaoyang District, Beijing 100105, China. Speakers: Xiaoming Zou, PhD, Chief Business Officer.

Eddingpharm (Cayman) Inc. and Chiesi Farmaceutici S.p.A to Establish Joint Venture to Promote Respiratory Therapeutics

Eddingpharm (Cayman) Inc. and Chiesi Farmaceutici S.p. A entered into a joint venture agreement regarding the establishment of Chiesi Edding Hong Kong Limited. Pursuant to the Agreement, Chiesi Edding is controlled as to 51% by Eddingpharm and 49% by Chiesi Farmaceutici respectively. Chiesi Edding will leverage the strong and substantial marketing platform of Eddingpharm to facilitate the wide and quick commercialization of the two key products of Chiesi Farmaceutici in the respiratory therapeutic area in China. In December 2012, according to the Agreement, Chiesi Edding entered into an exclusive distribution agreement with Chiesi Farmaceutici under which Chiesi Edding was granted the exclusive right to market and sell Foster(R) and CLENIL(R), the two key products of Chiesi Farmaceutici in the respiratory therapeutic area in China. This exclusive distribution agreement has an initial term of 11 years. Both Foster(R) and CLENIL(R) have recently been granted Imported Drug License by China's State Food and Drug Administration.

Similar Private Companies By Industry

Company Name Region
Sonetik Limited Asia
Polylight Technology Ltd. Asia
Sinocom Pharmaceutical, Inc. Asia
MiLOC Pharmaceutical (HK) Ltd. Asia
Goodman Medical Supplies Ltd. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eddingpharm (Cayman) Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.